USA Vs Europe: Who Is Leading the Diabetes Tech Race?

Acosta, Gonzalo; Brown, Spandana; Zand, Ashkan; Kansara, Abhishek; Sadhu, Archana R.

doi:10.1007/s11892-019-1237-z

Cited by 8 publications

(6 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…CGM systems measure the glucose level at regular intervals, 24 hours a day, and translate the measurements into data about glucose direction and rate of change [18]. On the basis of this information, CGM use without additional SMBG is as safe and effective as CGM use with SMBG support [20].…”

Section: Glucose Monitoring Systemsmentioning

confidence: 99%

“…The advance in their development to so-called smart pens has changed this [36]. Smart pens include a memory function to track insulin doses and often have Bluetooth connectivity to transfer data to a smartphone app [18]. These functions seem to help patients improve their glycemic control [36].…”

Section: Insulin Pensmentioning

confidence: 99%

“…In addition to digital diaries, it provides a dose calculator based on information on previous insulin doses, insulin on board, and current blood glucose levels. In addition, the app can be connected to some CGM systems [18,37,38]. This allows better diabetes management [39].…”

Section: Insulin Pensmentioning

confidence: 99%

“…The advances in all the aforementioned technologies seem to improve glycemic control and, consequently, QoL. Therefore, they fulfill the purpose of diabetes technologies [18]. However, more data, especially on long-term outcomes, are needed [8,25,42,76,95].…”

Section: Principal Findingsmentioning

confidence: 99%

See 3 more Smart Citations

Diabetology 4.0: Scoping Review of Novel Insights and Possibilities Offered by Digitalization (Preprint)

Eberle¹,

Stichling²,

Löhnert³

2020

Preprint

View full text Add to dashboard Cite

BACKGROUND Increasing prevalence of diabetes mellitus (DM) and associated morbidity, worldwide, justify the need to create new approaches and strategies for diabetic therapy. Therefore, the ongoing digitalization offers novel opportunities. OBJECTIVE The aim of this paper is to give an updated overview of available diabetes technologies and possibilities and novel insights in diabetes therapy 4.0. METHODS A scoping review was carried out. A search for literature was performed in electronic databases (MEDLINE (PubMed), Cochrane Library, EMBASE, CINAHL and Web of Science). The results were categorized by the type of technology that was presented. RESULTS Different types of technology (glucose monitoring systems, insulin-pens, insulin-pumps, closed-loop systems, mHealth-apps, telemedicine and electronic medical records) may help to improve diabetes treatment. The improvements affect glycemic control primarily. But, they also help to increase autonomy and quality of life of people who were diagnosed with DM. CONCLUSIONS Diabetes technologies developed fast over the last years and offer novel insights and a chance in diabetes therapy to improve and individualize diabetes treatment. Challenges that need to be addressed in the next years relate to data security, interoperability and the creation of standards. CLINICALTRIAL Not applicable.

show abstract

Section: Glucose Monitoring Systemsmentioning

confidence: 99%

Section: Insulin Pensmentioning

confidence: 99%

Section: Insulin Pensmentioning

confidence: 99%

Section: Principal Findingsmentioning

confidence: 99%

See 2 more Smart Citations

Diabetology 4.0: Scoping Review of Novel Insights and Possibilities Offered by Digitalization (Preprint)

Eberle¹,

Stichling²,

Löhnert³

2020

Preprint

View full text Add to dashboard Cite

show abstract

“…As a matter of course, there are many more technologies that have proven to be effective in diabetes management in general, for example, continuous glucose monitoring systems [ 15 , 16 ], continuous subcutaneous insulin infusions [ 17 , 18 ], and sensor augmented insulin pumps or closed-loop systems [ 19 , 20 ].…”

Section: Introductionmentioning

confidence: 99%

Clinical Effectiveness of Different Technologies for Diabetes in Pregnancy: Systematic Literature Review

Eberle¹,

Löhnert²,

Stichling³

2021

J Med Internet Res

View full text Add to dashboard Cite

Background Hyperglycemia in pregnancy occurs worldwide and is closely associated with health issues in women and their offspring, such as pregnancy and birth complications, respectively, as well as comorbidities, such as metabolic and cardiovascular diseases. To optimize the management of diabetic pregnancies, sustainable strategies are urgently needed. Investigation of constantly evolving technologies for diabetes that help to manage pregnancy and health is required. Objective We aimed to conduct a systematic review to assess the clinical effectiveness of technologies for diabetes in pregnancy. Methods Relevant databases including MEDLINE (PubMed), Cochrane Library, Embase, CINAHL, and Web of Science Core Collection were searched in September 2020 for clinical studies (2008-2020). Findings were organized by type of diabetes, type of technology, and outcomes (glycemic control, pregnancy- and birth-related outcomes, and neonatal outcomes). Study quality was assessed using Effective Public Health Practice Project criteria. Results We identified 15 randomized controlled trials, 3 randomized crossover trials, 2 cohort studies, and 2 controlled clinical trials. Overall, 9 studies focused on type 1 diabetes, 0 studies focused on gestational diabetes, and 3 studies focused on both type 1 diabetes and type 2 diabetes. We found that 9 studies were strong quality, 11 were moderate quality, and 2 were weak quality. Technologies for diabetes seemed to have particularly positive effects on glycemic control in all types of diabetes, shown by some strong and moderate quality studies. Positive trends in pregnancy-related, birth-related, and neonatal outcomes were observed. Conclusions Technologies have the potential to effectively improve the management of diabetes during pregnancy. Further research on the clinical effectiveness of these technologies is needed, especially in pregnant women with type 2 diabetes.

show abstract